Clinical efficacy against critical illness due to COVID-19 of CDK6 inhibitor palbociclib against severe COVID-19 has been previously reported,37 whereas JAK inhibitor baricitinib has even been approved by the Food and Drug Administration (FDA).33 The gene discussed is CDK6; the disease is COVID-19.